This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CKPT Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About Checkpoint Therapeutics Stock (NASDAQ:CKPT) 30 days 90 days 365 days Advanced Chart Get CKPT alerts:Sign Up Key Stats Today's Range$4.26▼$4.2650-Day Range$4.15▼$4.2952-Week Range$2.06▼$4.50VolumeN/AAverage Volume1.56 million shsMarket Capitalization$370.71 millionP/E RatioN/ADividend YieldN/APrice Target$4.33Consensus RatingHold Company Overview Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Read More Checkpoint Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreCKPT MarketRank™: Checkpoint Therapeutics scored higher than 6% of companies evaluated by MarketBeat, and ranked 921st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingCheckpoint Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCheckpoint Therapeutics has received no research coverage in the past 90 days.Read more about Checkpoint Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Checkpoint Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CKPT. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.63 Short InterestThere is no current short interest data available for CKPT. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.00% of the stock of Checkpoint Therapeutics is held by institutions.Read more about Checkpoint Therapeutics' insider trading history. Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CKPT Stock News HeadlinesTrunk and disorderly: Two Malaysians’ alleged 3am boot escape foiled at Woodlands CheckpointJuly 9, 2025 | msn.comTrunk and disorderly: Two Malaysians’ alleged boot escape bid foiled at Woodlands CheckpointJuly 8, 2025 | msn.comWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.July 26 at 2:00 AM | InvestorPlace (Ad)Checkpoint Therapeutics finalizes acquisition by Sun PharmaJune 1, 2025 | uk.investing.comSun Pharma Finalizes $416M Deal for Checkpoint Therapeutics, Inc. (CKPT)May 30, 2025 | insidermonkey.comCheckpoint Therapeutics shareholders approve Sun Pharma mergerMay 30, 2025 | investing.comCheckpoint Therapeutics Completes Merger with Sun Pharma SubsidiaryMay 30, 2025 | tipranks.comCheckpoint Therapeutics Announces Merger ProgressMay 24, 2025 | uk.investing.comSee More Headlines CKPT Stock Analysis - Frequently Asked Questions How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.09. When did Checkpoint Therapeutics' stock split? Checkpoint Therapeutics's stock reverse split before market open on Sunday, December 4th 2022.The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include TG Therapeutics (TGTX), Bionano Genomics (BNGO), Fortress Biotech (FBIO), NIO (NIO), uniQure (QURE), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/13/2025Today7/26/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CKPT CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Checkpoint Therapeutics$4.33 High Price Target$4.80 Low Price Target$4.10 Potential Upside/Downside+1.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.85 million Net MarginsN/A Pretax Margin-98,868.08% Return on EquityN/A Return on Assets-659.07% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual Sales$41 thousand Price / Sales9,041.59 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-9.06Miscellaneous Outstanding Shares87,020,000Free Float47,808,000Market Cap$370.71 million OptionableOptionable Beta1.18 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CKPT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.